Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Rivaroxaban Under Review for Risk of Interstitial Pneumonia: PMDA
January 29, 2014
- PAFSC’s Second Committee to Review Taiho’s Novel Anticancer Agent on Feb. 3
January 28, 2014
- MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation
January 28, 2014
- PAFSC’s First Committee Supports Approval of Second SGLT-2 Inhibitor Dapagliflozin
January 27, 2014
- FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA
January 27, 2014
- Health Minister Waits for Investigation Results on Novartis Involvement in “Sign” Study
January 27, 2014
- Comprehensive Strategy Proposal for “Japan NIH” Calls for Study on Legislation to Prevent Clinical Research Fraud by Autumn
January 27, 2014
- Expert Groups Call for Early Resumption of Active Recommendation for HPV Vaccines
January 27, 2014
- Regulatory Reform Council Eyes New Special System for Mixed Healthcare
January 24, 2014
- NHI Pricing of Generics Set to Undergo Major Revision to Help MHLW Achieve New Target; Promotion through Medical Fee Revision Also Planned
January 24, 2014
- DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
- Chuikyo OKs New NHI Drug Pricing Rules for FY2014 Revision
January 23, 2014
- Gov’t to Fully Implement Japan Version of “Compassionate Use” System in FY2015
January 23, 2014
- Final Decision on Active Recommendation for HPV Vaccines Will Be Made at Next Subcommittee Meeting: Minister
January 23, 2014
- Revised PAL to Ensure Drug Safety to Take Effect in Late November
January 22, 2014
- Novartis Sales Rep Involvement in Investigator-Initiated Trial “Extremely Regrettable”: Health Minister Tamura
January 22, 2014
- No Hand Raised for Additional Applicant Appeal for New Flu Vaccine Project, Quota for 25 Million People in Limbo
January 21, 2014
- HPV Vaccine Injection Site Pain Possible Cause of Chronic Pain: MHLW Subcommittees
January 21, 2014
- Prescribing of Torii’s Sublingual Cedar Pollinosis Treatment Cedartolen to be Restricted to Trained Doctors
January 21, 2014
- MHLW Approves Japan’s 1st SGLT-2 Inhibitor, Boehringer’s Anticancer Drug
January 20, 2014
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…